GNPX Quote, Financials, Valuation and Earnings

GlucoTrack, Inc. has a net margin of -- compared to Genprex, Inc.'s net margin of --. Genprex, Inc.'s return on equity of -900.4% beat GlucoTrack, Inc.'s return on equity of --.

Genprex, Inc. has a consensus price target of $7.50, signalling upside risk potential of 11060.71%. On the other hand GlucoTrack, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Genprex, Inc. has higher upside potential than GlucoTrack, Inc., analysts believe Genprex, Inc. is more attractive than GlucoTrack, Inc..

Genprex, Inc. has a beta of -0.771, which suggesting that the stock is 177.148% less volatile than S&P 500. In comparison GlucoTrack, Inc. has a beta of 0.300, suggesting its less volatile than the S&P 500 by 70.003%.

Genprex, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GlucoTrack, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Genprex, Inc. pays -- of its earnings as a dividend. GlucoTrack, Inc. pays out -- of its earnings as a dividend.

Genprex, Inc. quarterly revenues are --, which are smaller than GlucoTrack, Inc. quarterly revenues of --. Genprex, Inc.'s net income of -$3.8M is higher than GlucoTrack, Inc.'s net income of -$4.2M. Notably, Genprex, Inc.'s price-to-earnings ratio is -- while GlucoTrack, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genprex, Inc. is -- versus 6.72x for GlucoTrack, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Moderna, Inc. has a net margin of -- compared to Genprex, Inc.'s net margin of -19.69%. Genprex, Inc.'s return on equity of -900.4% beat Moderna, Inc.'s return on equity of -30.18%.

Genprex, Inc. has a consensus price target of $7.50, signalling upside risk potential of 11060.71%. On the other hand Moderna, Inc. has an analysts' consensus of $35.78 which suggests that it could grow by 29.16%. Given that Genprex, Inc. has higher upside potential than Moderna, Inc., analysts believe Genprex, Inc. is more attractive than Moderna, Inc..

Genprex, Inc. has a beta of -0.771, which suggesting that the stock is 177.148% less volatile than S&P 500. In comparison Moderna, Inc. has a beta of 1.109, suggesting its more volatile than the S&P 500 by 10.882%.

Genprex, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Genprex, Inc. pays -- of its earnings as a dividend. Moderna, Inc. pays out -- of its earnings as a dividend.

Genprex, Inc. quarterly revenues are --, which are smaller than Moderna, Inc. quarterly revenues of $1B. Genprex, Inc.'s net income of -$3.8M is higher than Moderna, Inc.'s net income of -$200M. Notably, Genprex, Inc.'s price-to-earnings ratio is -- while Moderna, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genprex, Inc. is -- versus 4.81x for Moderna, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Olema Pharmaceuticals, Inc. has a net margin of -- compared to Genprex, Inc.'s net margin of --. Genprex, Inc.'s return on equity of -900.4% beat Olema Pharmaceuticals, Inc.'s return on equity of -45.61%.

Genprex, Inc. has a consensus price target of $7.50, signalling upside risk potential of 11060.71%. On the other hand Olema Pharmaceuticals, Inc. has an analysts' consensus of $36.50 which suggests that it could grow by 34.14%. Given that Genprex, Inc. has higher upside potential than Olema Pharmaceuticals, Inc., analysts believe Genprex, Inc. is more attractive than Olema Pharmaceuticals, Inc..

Genprex, Inc. has a beta of -0.771, which suggesting that the stock is 177.148% less volatile than S&P 500. In comparison Olema Pharmaceuticals, Inc. has a beta of 1.870, suggesting its more volatile than the S&P 500 by 86.967%.

Genprex, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Olema Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Genprex, Inc. pays -- of its earnings as a dividend. Olema Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Genprex, Inc. quarterly revenues are --, which are smaller than Olema Pharmaceuticals, Inc. quarterly revenues of --. Genprex, Inc.'s net income of -$3.8M is higher than Olema Pharmaceuticals, Inc.'s net income of -$42.2M. Notably, Genprex, Inc.'s price-to-earnings ratio is -- while Olema Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genprex, Inc. is -- versus -- for Olema Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Recursion Pharmaceuticals, Inc. has a net margin of -- compared to Genprex, Inc.'s net margin of -3135.32%. Genprex, Inc.'s return on equity of -900.4% beat Recursion Pharmaceuticals, Inc.'s return on equity of -80.23%.

Genprex, Inc. has a consensus price target of $7.50, signalling upside risk potential of 11060.71%. On the other hand Recursion Pharmaceuticals, Inc. has an analysts' consensus of $6.33 which suggests that it could grow by 34.47%. Given that Genprex, Inc. has higher upside potential than Recursion Pharmaceuticals, Inc., analysts believe Genprex, Inc. is more attractive than Recursion Pharmaceuticals, Inc..

Genprex, Inc. has a beta of -0.771, which suggesting that the stock is 177.148% less volatile than S&P 500. In comparison Recursion Pharmaceuticals, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Genprex, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Recursion Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Genprex, Inc. pays -- of its earnings as a dividend. Recursion Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Genprex, Inc. quarterly revenues are --, which are smaller than Recursion Pharmaceuticals, Inc. quarterly revenues of $5.2M. Genprex, Inc.'s net income of -$3.8M is higher than Recursion Pharmaceuticals, Inc.'s net income of -$162.3M. Notably, Genprex, Inc.'s price-to-earnings ratio is -- while Recursion Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genprex, Inc. is -- versus 43.21x for Recursion Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.